UnitedHealth Group has committed $4 million to expand the University of Tennessee Health Sciences’ health hub model across Tennessee, aiming to increase access to preventive care and chronic condition support for underserved communities. The partnership, which includes funding from the United Health Foundation and technical assistance from UnitedHealth Group, will scale the network from five current hubs to 13 statewide locations by the end of 2027. This expansion is part of a broader strategic effort to address rural health disparities and strengthen local healthcare workforce pathways.

The new investment builds on nearly $2 million in support provided since 2022, marking a sustained commitment to improving health outcomes in the state. Dr. Peter Buckley, chancellor of the University of Tennessee Health Sciences, stated that the partnership helps reimagine care delivery by bringing preventive services closer to where people live. The initiative also focuses on creating sustainable funding models for health hubs and enhancing data sharing capabilities to improve integration.

Expansion Targets and Workforce Development

The expanded network aims to reach 200,000 residents across West, Middle, and East Tennessee. Beyond physical infrastructure, the partnership includes a significant focus on workforce development. UnitedHealth Group will collaborate with the UT Health Sciences College of Nursing and College of Medicine to advance career pathways in rural areas. These pathways include training for rural-focused physician assistants, nurse practitioners/midwives, and dual-certified health coaches/doulas.

Program Impact and Strategy

Since 2022, the existing health hubs have served more than 4,000 people through over 20,000 visits. More than half of the participants successfully lowered their blood pressure, reducing risks for serious health complications. The hubs offer screenings, health coaching, safe exercise groups, and healthy cooking classes in accessible community locations. Danielle Gray, executive vice president of UnitedHealth Group and chair of the United Health Foundation, emphasized that the initiative supports community-led solutions to improve access to care.

What the Numbers Show

The operational data from the pilot phase indicates high engagement relative to the number of hubs. With more than 20,000 visits generated by just five hubs since 2022, the model demonstrates strong community adoption. The clinical outcome—where more than half of participants lowered their blood pressure—suggests that the preventive care model effectively addresses chronic conditions like hypertension and diabetes. Scaling this model to 13 hubs could significantly amplify these public health benefits, particularly in rural counties where healthcare access is often limited.

The Centers for Medicare & Medicaid Services (CMS) announced on Tuesday that it will terminate the Medicare Part D Premium Stabilization Demonstration after the 2026 plan year, removing a federal subsidy that has suppressed prescription drug premiums and potentially raising costs for seniors beginning in 2027. The decision ends a voluntary demonstration introduced in 2025 to mitigate premium volatility following structural changes under the Inflation Reduction Act. CMS stated that Part D plan sponsors now possess sufficient experience under the redesigned benefit structure to develop bids without additional federal support, effectively returning the market to traditional conditions in 2027.

The program has delivered an estimated $9.8 billion in federal support over the past two years, with approximately $3.6 billion allocated this year alone. According to administration officials cited by The Wall Street Journal, had the demonstration continued into 2027, more than half of the funding would have been directed to UnitedHealth Group Inc. A UnitedHealth Group spokesperson affirmed the company’s commitment to working with CMS to ensure seniors retain access to affordable prescription medicines.

Premium Outlook for 2027

Administration officials outlined a fragmented outlook for Medicare Part D premiums in 2027. Roughly 25% of enrollees are expected to see premiums remain flat or decline, while about 30% could face monthly increases of less than $10. The remaining 45% are projected to see premium increases largely between $11 and $20 per month. Officials argued that insurers no longer require federal support and emphasized that affordable plan options will remain available for beneficiaries who compare plans carefully.

CMS Administrator Dr. Mehmet Oz defended the discontinuation on X, characterizing the previous administration’s approach as directing “billions of taxpayer money” directly to insurance companies. “We are stabilizing the market so this bailout is no longer needed,” Oz wrote. He added that premiums will rise by less than $10 for most beneficiaries, with many seeing lower costs, and noted that every beneficiary will continue to have access to low-cost plans. The administration also highlighted ongoing efforts to reduce drug prices, including expanding access to GLP-1 medications for $50 a month.

Market Drivers and Broader Context

Medicare drug plan premiums have risen due to growing costs for GLP-1 medicines and other specialty drugs. Juliette Cubanski, vice president at KFF, told The Journal that changes under the Inflation Reduction Act of 2022 lowered out-of-pocket costs for many beneficiaries but shifted a greater share of prescription drug costs to insurers. These cost pressures are expected to persist into 2027.

The policy change arrives amid broader financial stress for retirees. A recent Schroders survey found that retirees spend 16% of their monthly income on healthcare expenses, while 58% said they underestimated how much Medicare would cover. Additionally, Medicare Advantage coverage has become less stable, with roughly 2.6 million beneficiaries losing their prescription drug plans after insurers discontinued offerings or exited certain markets ahead of the 2026 plan year.

What the Numbers Show

The subsidy program significantly reduced average Medicare Part D premiums by about 40% in 2025 and 27% in 2026. Despite this federal support, insurers continued to reduce the number of available drug plans. The average premium for a Medicare Part D plan was about $36 a month this year, according to KFF. The removal of the subsidy exposes the underlying cost pressures driven by specialty drug utilization and regulatory shifts, suggesting that future premium stability will depend heavily on plan design choices rather than federal backstops.